PROMINENT (Completed) Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in diabetic patients Medicine pemafibrate Population Diabetes mellitus Phase III Starting year 2016 More information Clinicaltrials.gov Director of Study dr. F.M.A.C. Martens (Cardioloog) Deventer, Deventer Ziekenhuis